Advances in systemic treatments for metastatic kidney cancer

In this video interview Professor Jens Bedke from the Department of Urology, Eberhard Karls University Tübingen in Germany discusses the transformation in the first-line treatment of renal cell carcinoma (RCC) from tyrosine kinase inhibitors (TKIs), which was the standard of care, to combination therapies. First-line treatment with a combination of an immune checkpoint inhibitor and a TKI improved outcomes in patients with clear-cell metastatic RCC, compared with the current standard of care with a TKI alone. Professor Bedke reviews the data and the impact on clinical practice.

Watch the video interview on UroToday here

Share this Post!

Related post